A Public BCR Present in a Unique Dual-Receptor-Expressing Lymphocyte from Type 1 Diabetes Patients Encodes a Potent T Cell Autoantigen
Rizwan Ahmed,Zahra Omidian,Adebola Giwa,Benjamin Cornwell,Neha Majety,David R. Bell,Sangyun Lee,Hao Zhang,Aaron Michels,Stephen Desiderio,Scheherazade Sadegh-Nasseri,Hamid Rabb,Simon Gritsch,Mario L. Suva,Patrick Cahan,Ruhong Zhou,Chunfa Jie,Thomas Donner,Abdel Rahim A. Hamad
DOI: https://doi.org/10.1016/j.cell.2019.05.007
IF: 64.5
2019-01-01
Cell
Abstract:T and B cells are the two known lineages of adaptive immune cells. Here, we describe a previously unknown lymphocyte that is a dual expresser (DE) of TCR and BCR and key lineage markers of both B and T cells. In type 1 diabetes (T1D), DEs are predominated by one clonotype that encodes a potent CD4 T cell autoantigen in its antigen binding site. Molecular dynamics simulations revealed that this peptide has an optimal binding register for diabetogenic HLA-DQ8. In concordance, a synthetic version of the peptide forms stable DQ8 complexes and potently stimulates autoreactive CD4 T cells from T1D patients, but not healthy controls. Moreover, mAbs bearing this clonotype are autoreactive against CD4 T cells and inhibit insulin tetramer binding to CD4 T cells. Thus, compartmentalization of adaptive immune cells into T and B cells is not absolute, and violators of this paradigm are likely key drivers of autoimmune diseases.